CRISPR Therapeutics Q2 EPS $(0.98) Beats $(2.12) Estimate, Sales $70.00M Beat $1.71M Estimate
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics reported Q2 earnings per share of $(0.98), beating the analyst consensus estimate of $(2.12) by 53.77%. The company also reported quarterly sales of $70.00 million, surpassing the analyst consensus estimate of $1.71 million by 3.99K%. This represents a significant increase from the same period last year.
August 07, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock price.
CRISPR Therapeutics reported Q2 earnings and sales that significantly beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100